Research status and prospect of immunotherapy in gastrointestinal stromal tumors.
10.3760/cma.j.cn441530-20220428-00188
- Author:
X F SUN
1
;
X D GAO
1
;
K T SHEN
1
Author Information
1. Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Gastrointestinal Stromal Tumors/drug therapy*;
Prospective Studies;
Immunotherapy/methods*;
Tumor Microenvironment;
Protein Kinase Inhibitors/pharmacology*
- From:
Chinese Journal of Gastrointestinal Surgery
2023;26(1):102-106
- CountryChina
- Language:Chinese
-
Abstract:
Tyrosine kinase inhibitors (TKI) significantly reduce the risk of recurrence and metastasis and prolong survival in patients with gastrointestinal stromal tumors (GIST), but drug resistance is often inevitable. Immunotherapy has been proven effective in multiple solid tumors, but the efficacy in GIST is unclear. The efficacy of immunotherapy depends on the tumor microenvironment (TME). Tumor-infiltrating immune cells and immune checkpoints are important components of TME, which not only participate in the regulation of tumor immune response but are also the key target of immunotherapy. A comprehensive analysis of them can clarify the mechanism of tumor immune escape. This review found that there are abundant tumor-infiltrating immune cells in GIST, which play an important role in tumor immune surveillance and escape. Although early clinical studies have shown that patients with GIST have a good tolerance to immunotherapy, the curative effect is not satisfactory. Therefore, how to select the responders of immunotherapy and coordinate the relationship between immunotherapy and TKIs is the key issue to be explored. At the same time, the gradual deepening of basic research and large sample prospective clinical trials will certainly provide more strategies for the application of immunotherapy in GIST.
